Palvella Therapeutics PVLA
$142.85 −$2.92 (-2.00%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $142.85 0.00%
Open$143.10
Prev close$145.77
Day range$142.22 – $148.69
Volume192.7K
Market cap$2.09B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$22.73M-123.3% YoY
Net profit-$24.64M-117.2% YoY
Diluted EPS-$1.70-65.0% YoY
Free cash flow-$14.43M-83.1% YoY
Operating cash flow-$14.43M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-63.4%
Return on assets-49.0%
Return on invested capital-60.8%
Current ratio16.01
Liabilities / assets17.3%
Cash & investments$236.68M
Total debt$260,000.00
Net cash (debt)$236.42M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $22.73M | $21.41M | $14.86M | $38.60M | $11.30M |
| Selling and Admin Expenses | $11.90M | $8.93M | $5.52M | $15.76M | $4.18M |
| -General & Admin Expense | $11.90M | $8.93M | $5.52M | $15.76M | $4.18M |
| Research & Development | $10.82M | $12.47M | $9.33M | $22.84M | $7.12M |
| Operating Profit | -$22.73M | -$21.41M | -$14.86M | -$38.60M | -$11.30M |
| Net Non-Operating Interest Income (Expense) | -$263,000.00 | -$343,000.00 | -$966,000.00 | -$3.23M | -$1.22M |
| Non-Operating Interest Income | $2.55M | $1.97M | $1.07M | $2.59M | $520,000.00 |
| Non-Operating Interest Expense | $2.81M | $2.31M | $2.04M | $5.82M | $1.74M |
| Other Income (Expense) | -$1.65M | -$122,000.00 | $54,000.00 | $115,000.00 | -$191,000.00 |
| Gain on Sale of Security | -$1.65M | -$114,000.00 | $86,000.00 | -$612,000.00 | -$99,000.00 |
| Other Non-Operating Income (Expenses) | -$6,000.00 | -$8,000.00 | -$32,000.00 | $727,000.00 | -$92,000.00 |
| Pretax Profit | -$24.64M | -$21.87M | -$15.77M | -$41.72M | -$12.71M |
| Tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Profit | -$24.64M | -$21.87M | -$15.77M | -$41.72M | -$12.71M |
| Profit from Continuing Operations | -$24.64M | -$21.87M | -$15.77M | -$41.72M | -$12.71M |
| Net Income to Parent Company | -$24.64M | -$21.87M | -$15.77M | -$41.72M | -$12.71M |
| Net Income to Common Stockholders | -$24.64M | -$21.87M | -$15.77M | -$41.72M | -$12.71M |
| Basic EPS | -$1.70 | -$1.52 | -$1.20 | -$3.71 | -$1.08 |
| Diluted EPS | -$1.70 | -$1.52 | -$1.20 | -$3.71 | -$1.08 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $239.40M | $253.51M | $263.76M | $59.56M | $59.56M |
| Total Current Assets | $238.97M | $253.03M | $263.23M | $58.99M | $58.99M |
| Cash and Cash Equivalents & Short-Term Investments | $236.68M | $250.58M | $261.85M | $57.98M | $57.98M |
| -Cash and Cash Equivalents | $193.30M | $187.80M | $206.39M | $57.98M | $57.98M |
| -Short Term Investments | $43.38M | $62.78M | $55.46M | – | – |
| Other Current Assets | $2.29M | $2.44M | $1.38M | $1.01M | $1.01M |
| Total Non-Current Assets | $435,000.00 | $482,000.00 | $528,000.00 | $572,000.00 | $572,000.00 |
| Net PPE | $435,000.00 | $482,000.00 | $528,000.00 | $572,000.00 | $572,000.00 |
| -Gross PPE | $435,000.00 | $482,000.00 | $528,000.00 | $572,000.00 | $572,000.00 |
| Total Liabilities | $41.48M | $36.64M | $31.45M | $31.58M | $31.58M |
| Total Current Liabilities | $14.93M | $11.95M | $9.12M | $11.34M | $11.34M |
| Payables | $5.16M | $6.79M | $5.44M | $4.60M | $4.60M |
| -Accounts Payable | $5.16M | $6.79M | $5.44M | $4.60M | $4.60M |
| Current Accrued Expenses | $2.61M | $2.23M | $1.83M | $1.73M | $1.73M |
| Short-Term Debt and Capital Lease Obligation | $225,000.00 | $217,000.00 | $209,000.00 | $202,000.00 | $202,000.00 |
| -Current Capital Lease Obligation | $225,000.00 | $217,000.00 | $209,000.00 | $202,000.00 | $202,000.00 |
| Other Current Liabilities | $3.89M | $1.24M | $960,000.00 | $2.90M | $2.90M |
| Total Non-Current Liabilities | $26.55M | $24.70M | $22.33M | $20.23M | $20.23M |
| Long Term Debt and Capital Lease Obligation | $260,000.00 | $318,000.00 | $375,000.00 | $431,000.00 | $431,000.00 |
| -Long Term Capital Lease Obligation | $260,000.00 | $318,000.00 | $375,000.00 | $431,000.00 | $431,000.00 |
| Derivative Product Liabilities | $1.37M | $2.27M | $2.16M | $2.04M | $2.04M |
| Other Non-Current Liabilities | $24.92M | $22.11M | $19.80M | $17.76M | $17.76M |
| Total Equity | $197.92M | $216.87M | $232.31M | $27.98M | $27.98M |
| Stockholders' Equity | $197.92M | $216.87M | $232.31M | $27.98M | $27.98M |
| Capital Stock | $15,000.00 | $14,000.00 | $14,000.00 | $12,000.00 | $12,000.00 |
| -Common Stock | $15,000.00 | $14,000.00 | $14,000.00 | $12,000.00 | $12,000.00 |
| Additional Paid-In Capital | $395.58M | $389.85M | $383.42M | $163.34M | $163.34M |
| Retained Earnings | -$197.73M | -$173.09M | -$151.22M | -$135.45M | -$135.45M |
| Gains/Losses Not Affecting Retained Earnings | $56,000.00 | $89,000.00 | $95,000.00 | $83,000.00 | $83,000.00 |
| Receivables | – | – | – | $0.00 | $0.00 |
| -Accounts Receivable | – | – | – | $0.00 | $0.00 |
| -Taxes Receivable | – | – | – | $0.00 | $0.00 |
| -Preferred Stock | – | – | – | $0.00 | $0.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$14.43M | -$12.85M | -$10.86M | -$25.01M | -$4.93M |
| Net cash flow from continuing operations | -$14.43M | -$12.85M | -$10.86M | -$25.01M | -$4.93M |
| Net Income from Continuing Operations | -$24.64M | -$21.87M | -$15.77M | -$41.72M | -$12.71M |
| Gain/Loss from Continuing Operations | $1.12M | $114,000.00 | -$86,000.00 | $612,000.00 | $99,000.00 |
| Other Non-Cash Items | $3.15M | $1.98M | $2.02M | $5.88M | $1.80M |
| Change in Working Capital | $529,000.00 | $1.77M | -$406,000.00 | $3.82M | $3.80M |
| -Change in Prepaid Assets | $195,000.00 | -$1.07M | -$357,000.00 | $1.36M | $222,000.00 |
| -Change in Payables and Accrued Expense | $334,000.00 | $2.84M | -$49,000.00 | -$40,000.00 | $1.45M |
| Net cash flow from investing | $19.57M | -$7.03M | -$55.44M | – | – |
| Net Cash Flow from Continuing Investing Activities | $19.57M | -$7.03M | -$55.44M | – | – |
| Net Investment Purchase and Sale | $19.57M | -$7.03M | -$55.44M | – | – |
| Financing Cash Flow | $452,000.00 | $1.28M | $214.73M | -$660,000.00 | -$49,000.00 |
| Net Cash Flow from Continuing Financing Activities | $452,000.00 | $1.28M | $214.73M | -$660,000.00 | -$49,000.00 |
| Net Common Stock Issuance | $0.00 | $0.00 | $230.00M | – | – |
| Proceeds from Stock Option Exercised | $452,000.00 | $1.28M | $956,000.00 | $763,000.00 | $105,000.00 |
| Net Other Financing Charges | $0.00 | $0.00 | -$16.23M | -$1.42M | -$154,000.00 |
| Ending Cash Balance | $193.30M | $187.80M | $206.39M | $57.98M | $57.98M |
| Net Change in Cash | $5.60M | -$18.60M | $148.43M | -$25.67M | -$4.98M |
| Beginning Cash Balance | $187.80M | $206.39M | $57.98M | $83.60M | $63.57M |
| Effect of Exchange Rate Changes | -$102,000.00 | $6,000.00 | -$15,000.00 | $46,000.00 | -$610,000.00 |
| Free Cash Flow | -$14.43M | -$12.85M | -$10.86M | -$25.01M | -$4.93M |
| -Change in Receivables | – | – | – | $2.49M | $2.13M |
| Net Issuance Payments Of Debt | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on PVLA.
Sign in to join the discussion.